Diabetic foot ulcers (DFUs) pose a significant challenge to healthcare systems around the globe, affecting thousands of patients annually and often leading to increased morbidity, amputations, and healthcare costs. In a recent publication in the ’Journal of Wound Care’, Organogenesis Holdings Inc. reported compelling results from a randomized controlled trial that evaluated their innovative product, NuShield, against standard care for treating DFUs. This article dives into the findings of this pivotal study, the implications for regenerative medicine, and the potential impact on Organogenesis’ business trajectory.
Study Overview’
The clinical trial
Comments